Catherine Eckford (European Pharmaceutical Review)
Catherine Eckford is Editorial Assistant at European Pharmaceutical Review.
NewsLilly advances neuroscience portfolio with $7.8bn acquisition of Centessa
Acquisition includes a potential best-in-class asset for excessive daytime sleepiness, broadening Lilly’s capabilities into sleep medicine.
NewsUCB’s TK2d therapy Kygevvi approved by European Commission
Authorisation of the small molecule therapy in the EU represents a new option for thymidine kinase 2 deficiency, builds on earlier US FDA approval.
NewsFramework supports microbiota assessment in cleanroom changing rooms
Case study presents a potential benchmarking model for microbial trend data and a data presentation format for pharmaceutical cleanrooms.
NewsNovo Nordisk’s Awiqli first FDA-approved once-weekly basal insulin
The type 2 diabetes injection reduces administration frequency from daily to once per week, enhancing convenience for patients.
NewsMerck expands haematology pipeline with $6.7bn acquisition of Terns Pharmaceuticals
Deal strengthens Merck’s oncology portfolio with addition of a potential best-in-class oral TKI for chronic myeloid leukaemia.
NewsUCB positions new Georgia biologics facility as future US manufacturing hub
The biopharmaceutical company’s latest manufacturing venture represents one of the largest investments in Georgia’s history.
NewsAstraZeneca’s Imfinzi wins EU-first immunotherapy approval in early GI cancers
The approval represents the pharmaceutical company’s third perioperative approval in Europe for an Imfinzi-based regimen.
NewsGilead acquires potential first-in-class T cell engager in $2bn deal with Ouro Medicines
T cell engager gamgertamig could redefine standard of care for immune-mediated diseases.
NewsNanoparticle-exosome innovation could enhance cell therapy manufacturing
Novel, end-to-end process improves all four steps of exosome production simultaneously, supporting the design of more effective treatments.
NewsBMS wins dual immunotherapy-first approvals in classical Hodgkin Lymphoma
Expanded EU and US approvals for Bristol Myers Squibb’s Opdivo (nivolumab) position combination therapy as frontline option for the common blood cancer.
NewsNovartis strengthens its breast cancer pipeline with $3bn Synnovation acquisition
Deal to help address the significant unmet need in HR+/HER2- breast cancer and other advanced solid tumours.
NewsPennsylvania to house new actinium-225 manufacturing facility
Construction of TerraPower Isotopes’ cGMP facility increases its production capacity for the rare isotope, helping to boost global access to targeted alpha therapies.
NewsSandoz partners with Samsung Bioepis to accelerate biosimilar pipeline
New licensing, development and commercialisation agreement could expand Sandoz’s pipeline by to up to 32 assets.
NewsUpcycled plastic could facilitate production of Parkinson’s drug
Bioengineered E.coli provide an eco alternative to creating L-DOPA from terephthalic acid, suggests study.
NewsEli Lilly doubles down on supply chain investment in Asia
Pharma giant to strengthen manufacturing capabilities in Japan and add capacity in China for its first oral GLP-1 therapy candidate, orforglipron.
NewsSana's islet cell transplant therapy shows early promise in type 1 diabetes
Biotech company’s long-term data demonstrated hypoimmune (HIP)-modified islet transplantation without immunosuppression in type 1 diabetes.
NewsNeuro-specialist Lundbeck hires new AI lead
New recruit brings over 15 years of leadership experience to the brain health-focused biopharmaceutical company.
NewsChiesi and Bespak further collaboration to advance UK production of low carbon inhalers
Partnership increases industrial scale of low carbon pressurised metered dose inhalers (pMDIs), accelerating pharma’s transition to a more sustainable option.
NewsGSK grants rare disease firm Alfasigma rights to linerixibat for $690m
Licence agreement with the Italy-based pharma company to advance GSK’s ambitions in rare disease.
NewsStudy optimises automated de-bagging in aseptic manufacturing
Mechanical design improvements greatly enhanced success rate during primary de-bagging for double-bag products.